Antiretroviral therapy in AIDS patients with CMV disease: Impact on the survival and long-term treatment outcome

Journal of Infection

Volumn 56, Issue 1, 2008, Pages 40-43

  Sungkanuparph, Somnuek ^a   Chakriyanuyok, Taywin ^a   Butthum, Bodin ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Antiretroviral therapy; CMV; HIV; Survival; Treatment outcomes

Indexed keywords

PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CENTRAL NERVOUS SYSTEM INFECTION; COHORT ANALYSIS; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; FATALITY; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; KAPLAN MEIER METHOD; LONG TERM CARE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OPPORTUNISTIC INFECTION; PROPORTIONAL HAZARDS MODEL; RETINITIS; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT OUTCOME; VIRUS LOAD; VISUAL IMPAIRMENT;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COHORT STUDIES; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HIV-1; HOSPITALS, TEACHING; HUMANS; MALE; RETROSPECTIVE STUDIES; SURVIVAL RATE; THAILAND;

EID: 37149036791     PISSN: 01634453     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jinf.2007.10.005     Document Type: Article

References (22)

1. Jabs D.A., Holbrook J.T., Van Natta M.L., Clark R., Jacobson M.A., Kempen J.H., et al. Studies of ocular complications of AIDS Research Group: risk factors for mortality in patients with AIDS in the era of highly active antiretroviral therapy. Ophthalmology 112 (2005) 771-779
2. Holbrook J.T., Jabs D.A., Weinberg D.V., Lewis R.A., Davis M.D., Friedberg D., and Studies of Ocular Complications of AIDS (SOCA) Research Group. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol 121 (2003) 99-107
3. MacGregor R.R., Pakola S.J., Graziani A.L., Montzka D.P., Hodinka R.L., Nichols C.W., et al. Evidence of active cytomegalovirus infection in clinically stable HIV-infected individuals with CD4+ lymphocyte counts below 100/microliters of blood: features and relation to risk of subsequent CMV retinitis. J Acquir Immune Defic Syndr Hum Retrovirol 10 (1995) 324-330
4. Reichert C.M., O'Leary T.J., Levens D.L., Simrell C.R., and Macher A.M. Autopsy pathology in the acquired immune deficiency syndrome. Am J Pathol 112 (1983) 357-382
5. Mocroft A., Ledergerber B., Katlama C., Kirk O., Reiss P., d'Arminio Monforte A., et al. Decline in the AIDS and death rates in the EuroSIDA study: an observational study. Lancet 362 (2003) 22-29
6. Sterne J.A., Hernan M.A., Ledergerber B., Tilling K., Weber R., Sendi P., et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet 366 (2005) 378-384
7. O'Sullivan C.E., Drew W.L., McMullen D.J., Miner R., Lee J.Y., Kaslow R.A., et al. Decrease of cytomegalovirus replication in human immunodeficiency virus infected-patients after treatment with highly active antiretroviral therapy. J Infect Dis 180 (1999) 847-849
8. Salzberger B., Hartmann P., Hanses F., Uyanik B., Cornely O.A., Wöhrmann A., et al. Incidence and prognosis of CMV disease in HIV-infected patients before and after introduction of combination antiretroviral therapy. Infection 33 (2005) 345-349
9. Springer K.L., and Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J Antimicrob Chemother 54 (2004) 582-586
10. Mitchell S.M., Membrey W.L., Youle M.S., Obi A., Worrell S., and Gazzard B.G. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol 83 (1999) 652-655
11. Keane N.M., Price P., Lee S., Almeida C.A., Stone S.F., James I., et al. Restoration of CD4 T-cell responses to cytomegalovirus is short-lived in severely immunodeficient HIV-infected patients responding to highly active antiretroviral therapy. HIV Med 5 (2004) 407-414
12. Kempen J.H., Jabs D.A., Wilson L.A., Dunn J.P., West S.K., and Tonascia J. Mortality risk for patients with cytomegalovirus retinitis and acquired immune deficiency syndrome. Clin Infect Dis 37 (2003) 1365-1373
13. Morris A., Wachter R.M., Luce J., Turner J., and Huang L. Improved survival with highly active antiretroviral therapy in HIV-infected patients with severe Pneumocystis carinii pneumonia. AIDS 17 (2003) 73-80
14. Manosuthi W., Chottanapand S., Thongyen S., Chaovavanich A., and Sungkanuparph S. Survival rate and risk factors of mortality among HIV/tuberculosis-coinfected patients with and without antiretroviral therapy. J Acquir Immune Defic Syndr 43 (2006) 42-46
15. Jongwutiwes U., Kiertiburanakul S., and Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 5 (2007) 355-360
16. Vidal J.E., Hernandez A.V., de Oliveira A.C., Dauar R.F., Barbosa Jr. S.P., and Focaccia R. Cerebral toxoplasmosis in HIV-positive patients in Brazil: clinical features and predictors of treatment response in the HAART era. AIDS Patient Care STDS 19 (2005) 626-634
17. Jansen C.A., Piriou E., De Cuyper I.M., van Dort K., Lange J.M., Miedema F., et al. Long-term highly active antiretroviral therapy in chronic HIV-1 infection: evidence for reconstitution of antiviral immunity. Antivir Ther 11 (2006) 105-116
18. Lin D.Y., Warren J.F., Lazzeroni L.C., Wolitz R.A., and Mansour S.E. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy in HIV infected patients: natural history and clinical predictors. Retina 22 (2002) 268-277
19. Kirk O., Reiss P., Uberti-Foppa C., Gerstoft J., Pradier C., Wit F.W., et al. Safe interruption of maintenance therapy against previous infection with four common HIV-associated opportunistic pathogens during potent antiretroviral therapy. Ann Intern Med 137 (2002) 239-250
20. See R.F., and Rao N.A. Cytomegalovirus retinitis in the era of combined highly active antiretroviral therapy. Ophthalmol Clin North Am 15 (2002) 529-536
21. Wohl D.A., Kendall M.A., Owens S., Holland G., Nokta M., Spector S.A., et al., ACTG 379 Study Team. The safety of discontinuation of maintenance therapy for cytomegalovirus (CMV) retinitis and incidence of immune recovery uveitis following potent antiretroviral therapy. HIV Clin Trials 6 (2005) 136-146
22. Walmsley S.L., Raboud J., Angel J.B., Mazzulli T., Shen S., Casciaro L., et al. Long-term follow-up of a cohort of HIV-infected patients who discontinued maintenance therapy for cytomegalovirus retinitis. HIV Clin Trials 7 (2006) 1-9